Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02176941
Other study ID # 2014-A00298-39
Secondary ID
Status Recruiting
Phase N/A
First received June 26, 2014
Last updated June 15, 2016
Start date June 2014
Est. completion date November 2016

Study information

Verified date June 2016
Source Central Hospital, Nancy, France
Contact Athanase BENETOS, MD, PhD
Phone +33.3.83.15.33.22
Email a.benetos@chu-nancy.fr
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Observational

Clinical Trial Summary

The prevailing view in telomere epidemiology is that leukocyte telomere length (LTL) is associated with atherosclerosis and accelerated aging since it serves as a biomarker of the cumulative burden of inflammation and oxidative stress during adult life. Our recent results however, indicate that telomere length (TL) is mainly determined at birth and childhood. Since short telomeres ante cede atherosclerosis, the investigators hypothesize that TL is not just a simple marker, but a real determinant of arterial aging. That is because TL reflects cellular repair capacity and a short LTL denotes diminished repair reserves. This hypothesis cannot be tested by measurements of LTL alone, since this parameter reflects TL at birth and its age-dependent attrition thereafter. The investigators propose, therefore, a model that makes it possible to examine different elements of TL dynamics in different tissues: leukocytes, skeletal muscle, endothelial progenitor cells (EPCs), skin or subcutaneous fat in patients with or without atherosclerosis.

Our model is based on the following premises, which are derived from observations that TL is synchronized (equivalent) across somatic tissues/cells of the newborn:

- TL in skeletal muscle mainly reflects TL at birth

- The difference in TL between muscle and leukocytes in adults (approximately 1.5 Kbp) mainly reflects LTL attrition during the growth period, i.e., childhood/adolescence

- TL in EPCs determines the cell proliferative ability and therefore capacity for vessels repair during aging.

The general aim of the present project is to examine the links of arterial aging with TL, as expressed in different tissues, and LTL dynamics, as expressed in the difference between TLs of muscle and leukocytes.


Description:

Specific objectives:

1. To determine whether TL during early development, which is primarily reflected in muscle TL, and LTL attrition during development, which is primarily expressed in the difference between muscle TL and LTL, are associated with indices of arterial aging.

2. To examine the relation between EPC-TL to endothelial regenerative capacity and endothelial function. In order to attain this objective the investigators will perform two types of experiments:

- Measure TL in progenitor cells and relate it to clinical phenotypes of arterial aging and atherosclerosis, as well as markers of endothelial dysfunction

- Generate in vitro progenitor cells with different TL induced by the environmental factors (oxidative stress) and assess their phenotypes concerning inflammation and microvesiculation, in order to show a possible mechanistic relationship between TL in PC and the atherogenic and the regenerative capacities of these cells.

The project is composed of 6 tasks:

T1: Recruitment and sample collection (skeletal muscle, total blood) of 170 patients with atherosclerosis and 170 controls. Performed by surgeons and cardiologists of Marseille and Nancy University hospitals T2: Characterization of arterial aging in all patients (Geriatric Dpt, Univ. hospital Nancy, Pr Benetos and AP-HM, Internal Medicine, Marseille, Dr Rossi) T3: Characterization of early and late endothelial progenitor cells (EPC): laboratory of hematology and vascular biology and in UMR_S1076 in Marseille (Prs Dignat-George and Sabatier) T4: Measurements of TL in all samples (skeletal muscle, leukocytes and EPC): UMR_S1116 Nancy (Dr Lacolley) in collaboration with Pr Aviv (University of Medicine of New Jersey) T5: Characterization of inflammation markers in blood samples: UMR_S1116 and the UMR_S1122 (Dr Siest-Visvikis, Nancy) T6: Database construction and statistical analyses (UMR_S1116)

The results of this program could completely modify the present concept on the association between TL and cardiovascular risk: Actually, if our concept of early determination of TL is valid, therefore TL could be a true determinant of the arterial aging pace, through limitation of repair capacity of cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 340
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Men and women, aged = 20 years who are admitted for different types of surgery or for pacemaker/ defibrillator implantation and provide informed consent for participating in this study.

Exclusion Criteria:

Conditions which may impact telomere length:

- Patients undergoing surgery for cancer

- Patients who had had radiotherapy or chemotherapy.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
France AP Hôpitaux de Marseille Marseille
France Chu Nancy Nancy

Sponsors (5)

Lead Sponsor Collaborator
Central Hospital, Nancy, France Assistance Publique Hopitaux De Marseille, Institut National de la Santé Et de la Recherche Médicale, France, National Research Agency, France, University of Lorraine

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Measure TL in progenitor cells up to 3 years No
Primary Telomere Length (LT) dynamics TL dynamics: as expressed in the difference between TLs of muscle and leukocytes. up to 3 years No
Secondary Skin telomere length up to 3 years No
Secondary Subcutaneous fat telomere length up to 3 years No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03314818 - Natural History of Carotid Plaque as Determined by 3D Ultrasound N/A
Recruiting NCT03480568 - Alirocumab in Patients on a Stable Dialysis Regimen Phase 3
Completed NCT00673985 - Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study N/A
Completed NCT00090168 - Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED) Phase 3
Completed NCT00738725 - BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population N/A
Completed NCT00352222 - Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries Phase 3
Completed NCT02546648 - PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study Phase 3
Completed NCT02462005 - Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry.